Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
108.34
-2.07 (-1.87%)
Oct 1, 2026, 3:14 PM EDT - Market open
Halozyme Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12,296 | 7,914 | 6,083 | 4,882 | 7,694 | 5,659 | |
Market Cap Growth | 43.43% | 30.11% | 24.59% | -36.54% | 35.96% | -1.84% |
Enterprise Value | 14,243 | 8,751 | 6,951 | 5,929 | 8,940 | 5,722 |
Last Close Price | 110.40 | 67.30 | 47.81 | 36.96 | 56.90 | 40.21 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 32.02 | 24.98 | 13.70 | 17.34 | 38.06 | 14.05 |
Forward PE | 11.05 | 8.85 | 10.38 | 9.77 | 21.92 | 17.89 |
PS Ratio | 7.37 | 5.67 | 5.99 | 5.89 | 11.66 | 12.76 |
PB Ratio | 87.71 | 162.13 | 16.72 | 58.26 | 45.31 | 28.73 |
P/TBV Ratio | - | - | - | - | - | 28.73 |
P/FCF Ratio | 15.21 | 12.28 | 12.99 | 13.08 | 32.70 | 18.99 |
P/OCF Ratio | 14.98 | 12.15 | 12.70 | 12.57 | 32.04 | 18.90 |
PEG Ratio | - | 0.55 | 0.55 | 0.90 | 0.91 | 0.46 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 8.54 | 6.27 | 6.85 | 7.15 | 13.54 | 12.91 |
EV/EBITDA Ratio | 13.53 | 9.75 | 11.09 | 14.22 | 26.60 | 20.63 |
EV/EBIT Ratio | 15.05 | 10.72 | 12.61 | 17.56 | 30.89 | 20.74 |
EV/FCF Ratio | 17.63 | 13.58 | 14.84 | 15.88 | 37.99 | 19.20 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 15.18 | 44.60 | 4.14 | 18.27 | 9.07 | 4.47 |
Debt / EBITDA Ratio | 2.05 | 2.40 | 2.38 | 3.59 | 4.54 | 3.15 |
Debt / FCF Ratio | 2.70 | 3.38 | 3.22 | 4.10 | 6.55 | 2.95 |
Net Debt / Equity Ratio | 13.57 | 41.68 | 2.50 | 14.26 | 6.94 | 0.70 |
Net Debt / EBITDA Ratio | 1.85 | 2.27 | 1.45 | 2.87 | 3.51 | 0.50 |
Net Debt / FCF Ratio | 2.42 | 3.16 | 1.94 | 3.20 | 5.01 | 0.47 |
Asset Turnover | 0.72 | 0.61 | 0.54 | 0.46 | 0.45 | 0.53 |
Inventory Turnover | 2.48 | 1.95 | 1.77 | 2.36 | 2.67 | 2.04 |
Quick Ratio | 1.99 | 3.30 | 6.50 | 5.07 | 4.54 | 7.10 |
Current Ratio | 2.71 | 4.66 | 7.80 | 6.64 | 5.65 | 7.91 |
Return on Equity (ROE) | 173.67% | 153.59% | 198.42% | 222.07% | 110.23% | 231.44% |
Return on Assets (ROA) | 25.49% | 22.24% | 18.16% | 11.80% | 12.28% | 20.47% |
Return on Invested Capital (ROIC) | 32.13% | 33.01% | 34.44% | 20.77% | 27.92% | 105.98% |
Return on Capital Employed (ROCE) | 42.30% | 34.80% | 28.70% | 20.80% | 16.90% | 27.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.37% | 4.00% | 7.30% | 5.77% | 2.63% | 7.12% |
FCF Yield | 6.57% | 8.14% | 7.70% | 7.65% | 3.06% | 5.27% |
Buyback Yield / Dilution | 4.21% | 4.26% | 3.56% | 4.56% | 4.21% | -3.77% |